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Ultraviolet Radiation Perturbs Immune System,
Makes Mice More Susceptible to Tumor Growth
By perturbing the immune system, ultraviolet (UV) radiation
increases the susceptibility of mice to tumor growth. Experiments
by Margaret L. Kripke, PhD, and her associates in the Department of Immunology have revealed some of the complex
interactions between the immune system and UV radiation.
These experiments have shown that UV irradiation produces
specific and systemic changes in mice that weaken the immune
system and help skin cancers to grow. These findings raise
serious concern about the possible long-term effects of UV
radiation on the human immune system.

UV Irradiation Effects In Mice
The first direct evidence for a relation between UV irradiation
and the immune system came in experiments on tumor transplantation in mice. When mice were exposed to sufficient doses
of UV radiation, they developed fatal skin cancers. But when
these tumors were transplanted to syngeneic mice, few of them
grew. This failure surprised Kripke and other investigators
because most tumors induced in mice by chemical carcinogens
are readily transplantable among members of the same inbred
strain. In experiments she performed at the University of Utah,
Kripke showed that the failure was a result of immunologic
rejection- the tumors were highly antigenic.
"This high antigenicity in tumors with a long latent period
contradicted a long-held immunologic dogma," Kripke said recently in an interview. "The belief was that the longer the latent
period for a tumor, the less antigenic it was likely to be."
The highly antigenic nature of these tumors raised the question
of why they had not been rejected in the primary host. Kripke
attempted to answer this question in collaboration with Michael
Fisher, PhD, then a student at the University of Utah Medical
School. In these studies, mice exposed to UV radiation were
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unable to reject transplants of UV-induced tumors from syngeneic donors, even though they had been irradiated at a
different body site (Fig. 1). Thus, exposing the animals to UV
radiation produced a systemic effect: it interfered with the
immunologic rejection of UV-induced tumors even at unirradiated
sites. Furthermore, the time required to produce the systemic
effect was shorter than that necessary to induce primary tumors.
Kripke and Fisher delineated the nature of the UV-irradiated
mouse's failure to reject the tumors in a series of experiments on
lethally X-irradiated mice. When spleen and lymph node cells
from UV-treated donors were used to repopulate the lymphoid
organs of these lethally irradiated syngeneic mice, the recipients
were susceptible to tumor challenge. Lethally irradiated mice
given lymphoid cells from unirradiated donors, however, rejected
the tumor transplants. This experiment proved that the alteration
was immunologic, because it could be transferred with cells of the
immune system. In addition, when lymphoid cells from UVirradiated and unirradiated mice were mixed and used to repopulate the lymphoid organs of the X-irradiated mice, the transplants
were again not rejected, which suggested that a suppressor cell
population was involved. Kripke and Fisher and other investigators then showed specifically that suppressor T lymphocytes,
which are part of the immune regulatory system, were responsible for suppressing the immune response.

Role of Suppressor Cells
To study the role of suppressor cells in photocarcinogenesis,
Kripke and Fisher again gave lethal doses of X-irradiation to mice
and then repopulated the lymphoid organs with spleen and lymph
node cells from syngeneic normal mice or from mice irradiated
with sunlamps. Four weeks later pieces of dorsal skin from other
syngeneic mice that had been exposed to UV irradiation for 16
weeks were grafted onto these mice. Few tumors developed in
skin grafted to the mice that had received only normal lymphoid
cells, but many tumors developed in skin grafted to mice that had
_ __ eceivediymphot&cel1siromt:1~irradiateuuonors-onrmixture-o-r----cells from UV-irradiated donors and normal mice. This work
supported the hypothesis that UV-induced suppressor T lymphocytes dictate whether visible tumors will develop in UV-irradiated

skin.

Fig. 1. Mice exposed to UV radiation were unable to reject
transplants of UV-induced tumors from syngeneic donors,
whereas normal syngeneic mice rejected them.

In a companion experiment, mice were injected with T lymphocytes partially purified by separation on nylon wool columns, a
process that increases the proportion of T lymphocytes and the
suppressive activity of the preparation. The T lymphocytes had
been obtained from normal or from UV-irradiated syngeneic

Continued on page 2
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mice. Both treated and control mice were then exposed to UV
radiation. More mice that received T lymphocytes from UVirradiated donors developed tumors than did uninjected mice or
mice given normal T lymphocytes. In addition, skin cancers
began to appear around week 20 in the mice injected with the cell
population containing UV-induced suppressor T lymphocytes, but
only after week 40 in the other two treatment groups.
By these experiments, Kripke and Fisher showed that immunologic surveillance occurs during UV carcinogenesis. Immunologic surveillance eliminates or controls nascent tumors
arising early in the course of irradiation and is partly responsible
for the long latent period for induction of these skin cancers.
Earlier investigations had shown the immune surveillance system's effectiveness against tumor induction by oncogenic viruses; Kripke has demonstrated that a surveillance system also
participates in nonviral carcinogenesis.

Specificity of UV Radiation's Immune Effects
The next question posed by the results was the specificity of
the immune suppression: were mice immunosuppressed by UV
irradiation able to respond to other antigenic challenges? Further
research showed they were. Experiments showed that most
immune responses were intact in UV-irradiated mice (with the
exception of the contact hypersensitivity response to certain
chemicals, a response that is also suppressed). In fact, the UVirradiated mice could reject transplanted tumors from other
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strains of mice and even some syngeneic tumors induced by
chemicals or viruses. Thus, generalized immune suppression did
not seem to account for the failure of UV-irradiated mice to reject
the highly antigenic tumor transplants.
Later experiments provided further evidence for the specificity
of UV light's effects on the immune system. Kripke and her
associates obtained tumor cell lines derived from cloned mouse
fibroblasts transformed in vitro by UV radiation, 3-methylcholanthrene, or X rays. The growth of these cell lines was compared in
normal, UV-irradiated, and immunosuppressed mice. Only the
tumor lines produced by transformation with UV radiation grew
preferentially in UV-irradiated mice; the others grew equally well
in all three groups of mice. UV-induced suppressor T lymphocytes accounted for this prefereritial growth.
Additional dramatic evidence for this specificity was produced
by studies of skin cancer induced in mice by psoralen and UVA
(UV light in the 320- to 400-nm range) (PUVA). This combined
treatment produces many of the same biologic effects on skin
that are produced by sunlamp irradiation, including the formation
of skin cancers. Unlike UV-induced tumors, however, transplants
of PUVA-induced tumors grew at the same rate and with the
same incidence in normal and UV-irradiated mice.
Investigations by Kripke and Edward C. DeFabo, PhD, of
George Washington University, of the dose-response relation
between UV and these effects showed that susceptibility to tumor
challenge was proportional to UV dose regardless of dose rate,
number of exposures, and treatment duration. In fact, the effects
in mice were cumulative over long periods. For example, 12
exposures given over four weeks produced the same effect as
one exposure that was 12 times the single dose. Of potential
relevance to natural UV exposure is that the UV wavelengths that
were most effective in suppressing tumor rejection are present in
sunlight. Indeed, Kripke and several associates have recently
demonstrated that sun irradiation is capable of producing systemic immunologic changes in mice and guinea pigs.

Implications for Human Beings
The relevance of the UV light-skin cancer relationship in mice
to that in human beings is not clear-cut. The latent period for
photocarcinogenesis is very different in mice and people, the
latent period in humans being far longer. But photocarcinogenesis at the molecular level is most likely the same, according to
Continued on page 4
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Bone Marrow Transplantation Makes High-Dose
Cytoreductive Regimens, Remissions Possible
Karel A. Dicke, MD, PhD, Transplantation Center Chief,
Department of Hematology

Megadoses of treatment to eliminate malignant cells, whether it
consisted of combination chemotherapy and total body irradiation
or combination chemotherapy alone, has induced long-term
remissions and even "cures" in patients in whom conventional
doses of cytoreductive therapy failed to maintain remission or to
reinduce remission. Increasing the dosage, however, meant
increasing toxicity, usually gastrointestinal reactions and bone
marrow suppression.
Although physicians found no special therapeutic measures to
neutralize severe gastrointestinal toxicity, they did discover that
marrow transplantation could successfully restore hematopoiesis. Unfortunately, the proportion of patients who could benefit
from transplantation was very small because of the scarcity 9f
isogeneic and allogeneic donors. The proportion was narrowed
further by age restrictions, because only about half of the patients
who had suitable donors were considered young enough to
withstand the cytoreductive regimen. Therefore, physicians began using autologous bone marrow transplantation (ABMT) as a
protective measure against marrow suppression after high-dose
cytoreductive therapy.
The success of ABMT depends on (1) the cytoreductive
regimen, (2) the quality of the graft, and (3) the time of transplantation. The cytoreductive regimen usually involves either highdose chemotherapy or a combination of high-dose chemotherapy
and total body irradiation. Because the acute leukemias have
demonstrated the dose-response effect, most of the work with
ABMT has been done in the acute leukemias and most of what
follows is based on that work.
Cytoreductlve Regimen

Basic to choosing a drug for dose escalation in a conditioning
regimen is that its dose-limiting toxicity be myelosuppressive. In
addition, the drug's nonhematological toxicity should not be
cumulative and, of course, the increase in dose should lead to an
increase in remission rate. Only a few drugs can be escalated
fivefold or higher their usual maximum dose without producing
intolerable extramedullary toxicity. Melphalan is the, only drug
investigated so far that can be escalated sixfold (from 30 mg/m2
to 180 mg/~ 2 ) with the expected prolonged myelosuppression
and acceptable extramedullary toxicity. Cyclophosphamide and
etoposide have, even at a sixfold escalation, a rapidly reversible
myelotoxicity, but their use is limited by extramedullary toxicities.
Carmustine at an escalation of only fourfold and mitomycin at an
escalation of two- to threefold produce multiple extramedullary
toxicities. Amsacrine, when escalated fourfold, produces severe
gastrointestinal toxicity.
. We in the Department of Hematology at UT MDAH are
studying aziridinylbenzoquinone (AZQ), a drug that may have the
same potential for escalation that melphalan has. A synthetic
Vol. 30, No. 2

quinone compound, AZQ was designed for optimal central
nervous system penetration because of its lipid solubility and low
ionization potential. It has shown a broad spectrum of activity in
animal tumors, including intracranially implanted ependymoblastoma, 816 melanoma, P388 leukemia, L1210 leukemia, and
colon 26 cancer, and it has demonstrated antitumor activity in
several human neoplasms, including brain tumors, lymphoma,
and acute leukemias. At threefold the maximum dose, AZQ's
hematopoietic toxicity is pronounced but nonhematological toxicity is minimal, and it is at that level-when the drug is escalated
to 2.5 to 3 times the maximum dose-that responses occur.
We have found that the CBV regimen (6 mg/m2 of cyclophosphamide, 300 mg/m 2 of carmustine [BCNU], and 750 mg/m 2 of
etoposide [VP-16-213]) is an effective antileukemic regimen: two
of five patients who underwent allogeneic bone marrow transplantation during their second complete remission are now longterm survivors. In one study of 21 patients who had acute
myelogenous leukemia (AML) or acute lymphocytic leukemia
(ALL) who underwent CBV therapy, 12 (57%) achieved complete
remission after transplantation during relapse. In these patients
the CBV regimen was salvage therapy, which was tried after
other therapies had failed. In this same group, seven of 11
patients (63%) treated with CBV as a second salvage therapy
achieved complete remission, a rate dramatically better than the
9% complete remission rate achieved with conventional regimens.
It remains to be seen whether chemotherapy by itself is as
effective in eliminating leukemia as is the combination of irradiation and chemotherapy. Reports by European investigators are
beginning to show that the results are better when total body
irradiation is combined with the drug regimens. The value of highdose therapy can only be assessed in randomized studies or by
showing an increase in the success rate of salvage therapy with
patients who have poor prognoses. Our group is designing
cytoreductive protocols in which an approximate 75% remission
rate can be achieved in patients treated during relapse, resulting
in a small but meaningful fraction of long-term disease-free
survivors. Such a protocol will then be used to treat patients who
have less severe disease.

Quality of the Graft
One of the burning questions in treating a patient who has
acute leukemia with high-dose cytoreductive therapy is whether
autologous bone marrow can be used to restore hematopoiesis in
the recipient. Physicians know the hazard of transplanting
autologous marrow-the high chance that the marrow cell
suspension used for transplantation contains leukemic cells,
which may reinduce leukemia after transplantation .
The quality of the bone marrow depends on the quality of the
patient's remission at the time of marrow collection, the efficacy
Continued on page 5
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Kripke. The molecular lesions and effects produced in DNA by
UV light are similar in mouse and human cells. Differences in
repair capacity may explain the differences in the latent period:
the ability to repair UV-induced lesions in DNA is much lower in
mouse cells than in human cells. Patients with xeroderma
pigmentosum show a similar diminished repair capacity, and
they, too, quickly develop skin cancers when exposed to UV light.
It is not possible to demonstrate experimentally in humans the
same three-way relationship of UV irradiation, the immune
system, and photocarcinogenesis that has been demonstrated in
mice. Nevertheless, there is evidence that in man a relationship

exists between each of three possible pairs-the immune
system and photocarcinogenesis, UV irradiation and photocarcinogenesis, and UV irradiation and the immune system.
For example, there are suggestions that immunologic factors
participate in human photocarcinogenesis. That renal transplant

The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
Twenty-ninth Annual Clinical Conference

Diagnosis and
Treatment Strategies
for Gynecologic Cancer
November13-16, 1985
Shamrock Hilton Hotel, Houston
Chaired by Ralph S. Freedman, MD, PhD, David M.
Gershenson, MD, and Felix N. Rutledge, MD, Department
ot Gynecology.
The conference will present current knowledge on diagnosis and treatment of gynecologic malignant diseases
and highlight issues important to the practicing physician.
In addition to the more common endometrial, cervical, and
ovarian cancers, the conference speakers will deal with
such topics as the use of tumor markers and therapy with
biologic response modifiers.

patients have an increased risk of developing sunlight-associated
skin cancers is the first of these. Long-term immunosuppressive
therapy to suppress transplant rejection was believed to be a
possible contributor to this increased risk. The second is the
success of topical dinitrochlorobenzene (DNCB) treatment of
patients with multiple skin cancers-immunologic reactivity
against tumor tissue may play a role in the destructive process.
Third, there are a few reports of lymphoid cell infiltrates at the site
of human skin cancers, and in vitro assays of immunologic
reactivity against tumor tissue have been positive.
According to Kripke, there is a direct and known relation
between UV exposure and skin cancer in humans. "In fact," she
says, "the term 'healthy tan' is an oxymoron. Although it is true
that a darker skin will protect you from some of the sun's
damaging effects, the tan itself is actually a response to damage."
In addition, Kripke explains that the relation between skin cancer
and UV exposure from the sun is a direct dose-response relation:
"Skin cancer is most related to total cumulative UV exposure and
to genetic susceptibility. If you have a good tanning response,
you are less likely to develop skin cancer, but with sufficient
exposure to UV, even people who tan can develop skin cancers."
Evidence that UV exposure has an effect on the immune
system of humans has been developed recently in Australia.
According to Kripke, ''The cult of sun worship is even stronger in
Australia than in the United States. Ironically, the Australian
population as a whole is even more genetically susceptible to
photocarcinogenesis than Americans are."
Because sun exposure is such a problem in Australia, dermatologist Dr Peter Hersey and his colleagues in Australia
studied the effects of salon tanning and sunbathing on the
immune system. "Insofar as we can determine, the changes he
found in human beings are similar to some that occur in mice
exposed to UV radiation," Kripke said. In UV-exposed Australians, the response to contact allergens was reduced, a result that
is analogous to the changes found in experiments performed on
mice and guinea pigs. Following irradiation with UV light, these
animals failed to demonstrate contact allergy to topically applied
chemicals. In addition, the numbers of T and B lymphocytes were
changed in the n~man §Ubj~..£!S, - • ··- - . ·- - - -- - -
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Therapeutic Potential

Because the immune system is pivotal in maintaining the
body's integrity, protecting it from infectious microorganisms,
toxic chemicals, and even some cancers, the disturbance of
immune responses by environmental radiation may be a serious
problem. On the other hand, it would often be highly desirable to
redirect the immune system toward a pathway of specific
- --1--- - - - - - - - - - - - - - - - - - - - -----t-- - -----uunresponsiveness-te-;g--;-;-in-organ-1ransplantation;-contact-atter------------Registration fees are $200 (in advance) and $250 (on
gies, and autoimmune reactions). Further advances by Kripke
site).
and others who are working in the new science of photoimmunology may lead to ways of exploiting the therapeutic potential of UV
For registration information, contact Shirley Roy, Office of
light and overcoming its deleterious effects.
Conference Services, HMB Box 131, The University of
(Physicians who desire additional information should write
Texas M. D. Anderson Hospital and Tumor Institute at
Margaret L. Kripke, PhD, Department of Immunology, MDAH Box
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
178, The University of Texas M. D. Anderson Hospital and Tumor
713/792-2222.
Institute at Houston, 6723 Bertner Avenue, Houston, Texas
77030-ED.)
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of eliminating residual leukemic cells from the marrow suspension, and the storage procedure.
The speed of myeloid hematopoietic recovery in humans after
transplantation has been shown to be directly proportional to the
number of granulocyte-macrophage colony-forming cells (GMCFCs) infused. Studies comparing the marrow of patients with
leukemia in remission with that of hematologically normal individuals have shown that the GM-CFC concentration in marrow
from the patients is 50% that in marrow from normal individuals.
Because 0.5 x 108 cells/kg of body weight from hematologically
normal individuals are needed for optimum engraftment, twice
that, or 1 x 108 , are needed when marrow from patients in
remission is used.
At remission, the number of leukemic cells in the marrow may
vary from 102 to 1010. We consider 108 cells a realistic estimate,
though of course the actual number depends on the quality of the
patient's remission. If we assume a homogeneous distribution of
leukemic cells in the marrow, the number of leukemic cells in the
marrow cell suspension to be transplanted is 106 , inasmuch as
1% of the entire bone marrow reserve is aspirated during marrow
harvest. Currently, no satisfactory assay exists for reliably
predicting hemoimmunologic reconstitution, and because we
cannot yet identify the number of clonogenic leukemic cells,
every leukemic cell must be removed.
To purge leukemic cells from marrow, researchers have used
monoclonal antibodies and complement, immunotoxins linked to
monoclonal antibodies, magnetic microspheres bound to monoclonal antibodies, rat monoclonal antibody cytotoxic "cocktails,"
and colloidal immunomagnetic fluids. None of the methods,
though, could demonstrate in a clinical setting more than a 2-log
reduction of tumor cells, and a 6-log kill is believed necessary.
Furthermore, although some of the chemicals employed did
destroy leukemic cells, they also reduced the GM-CFC population. In our studies we are evaluating such drugs as L-asparaginase, vincristine, bleomycin, and possibly spirogermanium,
which can be used at relatively high concentrations in vitro
without compromising the hematopoietic restoration potential.
To ensure the viability of the hematopoietic stem cell population afterwards, we monitor the following four factors in storing
marrow for transplantation: (1) composition of the cells to be
stored, (2) freezing procedure, (3) temperature at which the cells
are stored, and (4) manipulation of the cells after storage.
Granulocytes and platelets in the cell suspension decrease stem
cell viability after storage, but they can be removed effectively
before freezing by Haemonetics centrifugation or by the use of
Ficoll-Hypaque or Percoll gradients. Generally, the cells are
frozen at a rate of 1°C/minute from 4°C to -40°C and stored in
liquid nitrogen at -156°C. When the time for transplantation
arrives, the cells are rapidly thawed in a 50°C water bath and
infused immediately without being diluted.

Time of Transplantation
The best time for transplantation, we think, is when the
patient's disease is minimal. The best time for studying the
Vol. 30, No. 2

effectiveness of transplantation is when the disease has reached
a phase at which conventional doses of chemotherapy no longer
induce a long-term remission, yet when the tumor still responds
to high-dose cytoreductive therapy in conjunction with infusion of
marrow free of leukemic cells (e.g., from isogeneic-identical
twin-donors). When such treatment induces long-term diseasefree survival in a substantial proportion of patients (30%-50%), it
indicates that high-dose cytoreduction is still effectively eradicating residual leukemic cells. (The long-term survival rate of
relapsed patients treated only 1O years ago with conventional
therapy was close to zero.) We believe that patients in a second
remission from AML and second and subsequent remissions
from ALL fulfill these criteria.
In our experience, performing transplantation during relapse
does not offer the best opportunity to assess the role of purging
bone marrow of \eukemic ce\\s, because the remission after
transplantation is short. If reports from several teams are
compiled, we see that of 95 patients who had relapsed with acute
leukemia and undergone autologous bone marrow transplantation, 60 achieved complete remissions. Unfortunately, complete
remissions lasted for a median of only six months (range, 1 + to
38 months), and only four patients, fewer than 5% of the entire
population undergoing transplantation during relapse, remained
in continuous complete remission for two years. Relapse after
high-dose treatment is predominantly because of residual disease.
Performing transplantation during a patient's first complete
remission may also present difficulties in evaluating the effectiveness of transplantation, because the prognosis of a patient
after bone marrow transplantation is based on the length of the
complete remission before transplantation. Of patients whose
first complete remission lasts six months, 25% can expect to
have long-term disease-free survival, whereas more than 75% of
the patients who remain in first complete remission for more than
two years achieve long-term disease-free survival with conventional chemotherapy (Fig. 1). Careful analysis of the timing of
transplantation is necessary, therefore, to assess the contribution
of transplantation to long-term survival.

ABMT and Acute Leukemia
Although the low number and diversity of the patients studied
prevent conclusions from being drawn about the role of ABMT in
acute leukemia, some promising early data come from physicians
using purged marrow. At Johns Hopkins Oncology Center,
researchers studying ABMT in patients in second and subsequent remission from AML have treated 15 patients with purged
marrow. Five are in continuous complete remission more than.
one year after treatment.
Reports of patients treated with unpurged marrow are less
promising. In one study, of 10 AML patients treated with
nonpurged marrow, only one is alive more than three years after
transplantation. Preliminary data from our two-part study of a
group that was treated during second or third complete remission
with CBV and nonpurged marrow show that only one patient of 11
had a transplantation remission longer than the remission before
transplantation. We found also that on rare occasions this
phenomenon can be achieved with chemotherapy in convenContinued on page 6
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tional doses, as it was in one patient in this group. This patient's
first complete remission lasted 24 months and the second
complete remission lasted 93 months. In the 11 patients undergo·ing transplantation, median duration of the transplantation remission was 7.5 months, whereas the median duration of the
preceding remission was 14 months.
Of 29 patients with ALL in second and subsequent remissions
treated at Johns Hopkins with purged marrow, only three have
achieved two-year disease-free survival. In a study at Duke
University Medical Center, of 24 patients with ALL in second
complete remission, nine are still in remission, five of these
\onger than one year. \n two of these patients, the duration of the
transplantation remission exceeds the preceding remission,
which is seldom the case in patients treated with conventional
chemotherapeutic protocols.

ABMT and Hodgkin's Disease
10 ◄ •

Our group's results in treating Hodgkin's disease with highdose CBV chemotherapy and ABMT are also promising. Of 16
adult patients with progressive or relapsed Hodgkin's disease, 12
had progressive disease at the time of transplantation. Thirteen
patients had undergone three or more previous salvage chemotherapies, and the same number had also had radiotherapy. Of
the 16 patients treated, six achieved complete remission and six
a partial response. Only four did not benefit. Responders
survived a median of 15 months. Three of the 16 are alive and
disease free at more than 44, 16, and 14 months after transplantation.

I.JEEKS

Fig. 1. Influence of duration of complete remission (CR) on
chance of continuous long-term disease-free survival. The
horizontal axis indicates the time in weeks, and the vertical axis
the percentage of patients surviving disease free. Twenty-six
percent of the patients who are in CR for six months (triangles)
and 38% of those who are one year in CR (X) are long-term
survivors; the percentage increases to 78% when the patients
remain in CR for 24 months (diamonds). When patients are in CR
for 36 months or longer (top line, arrow), the figure increases to
95%. (Reprinted with permission from Autologous Bone Marrow
Transplantation: Proceedings of the First International Symposium, edited by K. A. Dicke, G. Spitzer, and A. R. Zander.)

ABMT and Small Cell Bronchogenlc Carcinoma
Work done by our group and others indicates that the natural
history of small cell bronchogenic carcinoma in patients who have
extensive disease but achieve a complete remission cannot yet
be influenced by high-dose cytoreductive protocols. These regimens do produce favorable results, however, in patients whose
disease is \imited and who are able to achieve complete
remission after three initial courses of normal chemotherapy. Five
of 13 patients who underwent transplantation at UT MDAH have
achieved long-term (more than two years) disease-free remissions. There appears to be no difference in the percentage of
patients who achieve disease-free survival between patients who
achieve complete remission early in conventional treatment and
those who achieve complete remission after additional courses of
induction chemotherapy at conventional doses (in both groups,
about 10% achieve disease-free survival). Though the numbers
in our study are small, it is encouraging that five of 13 patients
(38%) are potential long-term disease-free survivors, particularly
since only nine of these 13 underwent the total two courses of
intensified therapy, including high-dose chemotherapy and chest
irradiation.
We have introduced multiple transplants (administering more
than one course of high-dose chemotherapy and following with
ABMT) in treating this tumor. By doing this we can increase the
normal dose of Cytoxan (cyclophosphamide) and etoposide

6

sixfold with acceptable nonhematopoietic toxicity. Furthermore,
because solid tumors respond best after more than one course of
conventional cytoreductive therapy, sequential administration of
high-dose cytoreductive therapy is logical.

Conclusion
Rescue by autologous bone marrow transplantation is still in its
infancy. Work continues, not only in leukemia, lymphomas and
Hodgkin's disease, and small cell bronchogenic carcinoma, but
also in breast cancer, neuroblastoma, primary tumors of the
central nervous system, melanoma, and testicular and ovarian
cancers. The intent is to develop curative treatment. We believe
that developing assays, purging methods, and new cytoreductive
regimens are difficult tasks but that striking results await us and
others working in this field. These will come when, after ABMT
produces an approximate 75% remission rate and a resulting
proportion of long-term disease-free survivors of advanced
disease, it can be used to treat disease at an early stage.
(Physicians who desire additional information should write
Karel A. Dicke, MD, PhD, Transplantation Center Chief, Department of Hematology, MDAH Box 55, The University of Texas
M. D. Anderson Hospital and Tumor Institute at Houston, 6723
Bertner Avenue, Houston, Texas 77030.-ED.)
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Psychological and Social Cures Next
for Children Who Recover from Cancer
In the 1990s, only a few years hence, cancer in children will be
accepted as a normal illness of childhood. This celebrates the
fact that ''the care and cure of cancer in children is decades
ahead of the care and cure of cancer in adults," Jan van Eys,
PhD, MD, said at UT MDAH's Tenth Annual Mental Health
Conference. But it requires clinicians involved in children's
biologic cancer treatment to be concerned now with the children's
psychological and social cures-their return to ordinary living in
family, school, and community.
In his summary of the conference, Childhood Cancer Survival:
Living Beyond Cure, held April 11-12 in Houston, van Eys,
Mosbacher Professor of Pediatrics and head, Division of Pediatrics, recalled that a decade ago the first of these meetings
introduced the concept of the "truly cured child," a child "developmentally and educationally on par with peers in spite of the
experience with cancer.,"
The challenge today, he said, is ''the acceptance of cancer as
another normal illness of childhood." This goal is achievable
because psychological adjustment and social acceptance follow,
though not without effort, when an illness comes to be seen as
curable.
Referring to the sequential stages in care (Table 1) and control
(Fig. 1), van Eys said they are circular, one depending on and
following the other. He compared the socialization problems of
children with cancer with the racial integration struggles of the
sixties.
"Whenever a profound social change occurs," he said, ''there
are usually two driving forces. The first, and rarely the primary
cause, is a significant and fundamental rethinking of basic
principles. A second force is economic. The redistribution of
health care costs is going on whether we like it or not. Cancer and
its treatment are simply too expensive for society to maintain as a
unique approach. Financially, cancer will become just another
disease, and that perception will be generally seen within the next
decade. Cancer patients will be just another group of people."
But cure has its consequences, he said. "There are physical

Table 1. Stages in Cancer Care
1945

Recognition of childhood cancers as treatabledevelopment of chemotherapy.

1960

Recognition of the psychosocial struggle for the
patient-death and dying movement.

1975

Recognition of cure as the expected outcomethe truly cured child.

1990

Acceptance of cancer as another norma\ i\\ness of
childhood-the normally sick child.

defects to overcome, psychological handicaps, social barriers,
and genetic uncertainties. Those are the burdens of the cured
child."
As long as these children were considered as special persons,
he said, "'rescued from the dead,' strangers in a strange land,
they were received with open arms and yet, because of special
status, excluded from society. As society begins to accept them
as just another patient, they have to shed their self-image of
strangeness. They have to feel integrated."
Biologic cure still carries a high cost to patient and society, he
said, and psychological cure faces great obstacles because of
that cost. Social cure is handicapped by the threat of later
recurrence of the illness.
"The patient still has to adapt," he said," to having had cancer.
All the reasons why a truly cured child is a necessary and realistic
goal of cancer care apply, but now the normally sick child must
also be a necessary and realistic goal for the care-giving
community and the patient."
Van Eys predicted a clamor for simplification of therapy and a
"strong push" away from large clinical trials. "The next challenge
in our care for cancer is to work on the end point of the circle," he
said. "We need to simplify our care, and understand that care is
not effective unless and until it can be made part of everyday life."
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Fig. 1. Evolution of the control of childhood cancer.
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Patients with Uver Cancer
in Drug Infusion Trial
Programmable, implantable infusion devices now make it
possible to provide more accurate arterial hepatic chemotherapy
for patients who have primary and secondary liver neoplasms.
Studies with the lnfusaid percutaneously implantable pump
and a new combination of drugs, cisplatin and floxuridine
(FUDA), have been done during the last two years at UT MDAH
by Yehuda Z. Patt, MD, associate professor of medicine and chief
of \the Regional Therapy Service of the Division of Medicine, and
Arthur W. Boddie, Jr, MD, associate professor of surgery, with
patients whose colon cancer metastasized to the liver.
A newer type of infusion device is the Medtronic pump. Like the
lnfusaid pump developed earlier, it is implanted directly and
completely under the abdominal skin. The ability to program the .
Medtronic pump with an external wand, Patt explained, gives
physicians more versatility than was possible before in changing
chemotherapy regimens and altering treatment intervals.
The procedure involves intravenous hydration of the patient
with 150 ml/hour of normal saline for 36 hours, both before and
-after-two-hour arterial infusioA ot 100..mg/~ef <;isp/atin.- Quring
cisp\atin administration with the arteria\ pump, 300 ml of 3%
saline and mannitol are infused intravenously. This is followed by
arterial infusion of 100 mg/m 2 /day of FUDR for five days. At the
end of this period, the treatment team evacuates the pump and
refills it with 20 ml of heparinized saline (500 units/ml).
The pump is then programmed to deliver 0.6 to 0.72 ml of the
saline solution per day, at a "keep open" rate that gives the
patient a 26- to 32-day interval at home until the next arterial
infusion treatment and reprogramming session.
Patt's recent phase II trial with this chemotherapeutic regimen
included 29 patients and involved infusion with the Medtronic
pump, the lnfusaid pump, and percutaneously placed arterial
catheters.
Four patients achieved a complete remission and 11 a partial
remission-a response rate of 52%. Median survival for the total
group was 12 months, despite some patients' extrahepatic
disease and a few patients' extensive liver disease. In those who
responded to treatment, Patt said, the extent of liver disease did
not affect survival. Among the nonresponding patients, he ·
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explained, those who had less severe disease survived twice as
long as did those whose cancer was more advanced.
"Our patients have to be very faithful, of course, in having their
pumps checked," he said. "But they are happy with them-they
are at home and working, and some are playing tennis, swimming, running, jogging, or playing racquetball."
To determine the role of cisplatin in the drug combination, Patt
and his team are now conducting a larger randomized trial of
FUDR alone and FUDR and cisplatin in a study in which they
hope to include more than 100 patients.
"The advent of implantable infusion devices," Patt said, "has
made large-scale hepatic arterial studies feasible. Most attractive
for patients is the convenience of not having to stay in the hospital
during the entire treatment and being able to continue their
normal activities between intensive treatment sessions."
Arterial infusion is still costly, he said, both because of the
pump's initial price and the cost of the surgical procedure to
implant it. "But the pump has made long-term treatment more
economical," he said, "because pump implantation is much less
expensive than the repeated and longer hospital admissions
required for drug infusion through catheters."
He cautioned that hepatic ~rterial chemotheraw for liver
metastasis j s _still_ experimental and can only be done \n a
research center. Optimal drug regimens remain to be discovered,
and FUDR has been reported to cause hepatitis and biliary
sclerosis in some patients.
"Modern technology has brought us some excellent infusion
devices," Patt said, "but our drug development has lagged. We
must find new and better combinations."
His group's initial results with FUDR and cisplatin suggest that
the combination is a good one, Patt said, but a confirmatory trial
is essential.
"The versatility of the Medtronic infusion device will allow us,
we hope, to complete a large trial and go on to next-generation
studies," he said, referring to expected technological improvements in the implantable devices and more effective drug
combinations.
(Physicians who desire additional information should write
Yeh~~a Z. Patt, MD, Regional Therapy Service, Division of
Medicine, MDAH Box 41, The University of Texas M. D.
Anderson Hospital and Tumor Institute at Houston, 6723 Bertner
Avenue, Houston, Texas 77030-ED.)
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